{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:52:14Z","timestamp":1789786334559,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40259-018-0265-6","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T13:04:56Z","timestamp":1519304696000},"page":"119-128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Guselkumab for the Treatment of Psoriasis"],"prefix":"10.1007","volume":"32","author":[{"given":"\u00c1lvaro","family":"Machado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"issue":"3","key":"265_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","volume":"41","author":"SR Rapp","year":"1999","unstructured":"Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3):401\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"265_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385.","journal-title":"J Invest Dermatol."},{"issue":"2","key":"265_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/jid.1952.72","volume":"19","author":"MB Sulzberger","year":"1952","unstructured":"Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol. 1952;19(2):101\u20132.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"265_CR4","first-page":"555","volume":"301","author":"W Mueller","year":"1979","unstructured":"Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301(10):555.","journal-title":"N Engl J Med"},{"issue":"14","key":"265_CR5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40265-017-0794-1","volume":"77","author":"T Torres","year":"2017","unstructured":"Torres T. Selective interleukin-23 p19 Inhibition: another game changer in psoriasis? Focus on Risankizumab. Drugs. 2017;77(14):1493\u2013503.","journal-title":"Drugs."},{"issue":"3","key":"265_CR6","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.4049\/jimmunol.176.3.1908","volume":"176","author":"G Piskin","year":"2006","unstructured":"Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176(3):1908\u201315.","journal-title":"J Immunol"},{"issue":"9625","key":"265_CR7","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675\u201384.","journal-title":"Lancet"},{"issue":"5","key":"265_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2015.12.017","volume":"74","author":"BE Strober","year":"2016","unstructured":"Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016;74(5):851\u201361.e4.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"265_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356. e4.","journal-title":"N Engl J Med"},{"issue":"3","key":"265_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Blauvelt A, Reich K, Tsai T-F, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"265_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1358\/dot.2017.53.5.2613690","volume":"53","author":"L Puig","year":"2017","unstructured":"Puig L. Brodalumab: the first anti-IL-17 receptor agent for psoriasis. Drugs Today. 2017;53(5):283.","journal-title":"Drugs Today"},{"issue":"4","key":"265_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et al. Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"9993","key":"265_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CEM Griffiths","year":"2015","unstructured":"Griffiths CEM, Reich K, Lebwohl M, Van De Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"4","key":"265_CR14","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/bjd.15666","volume":"177","author":"K Reich","year":"2017","unstructured":"Reich K, Pinter A, Lacour JP, Ferrandiz C, Micali G, French LE, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014\u201323.","journal-title":"Br J Dermatol"},{"issue":"14","key":"265_CR15","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328.","journal-title":"N Engl J Med"},{"issue":"3","key":"265_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen Y-K, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"key":"265_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","volume":"67","author":"GE Fragoulis","year":"2016","unstructured":"Fragoulis GE, Siebert S, Mcinnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annu Rev Med. 2016;67:337\u201353.","journal-title":"Annu Rev Med"},{"issue":"2","key":"265_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1501646","volume":"373","author":"KB Gordon","year":"2015","unstructured":"Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, et al. A Phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"265_CR19","first-page":"42","volume":"38","author":"RG Langley","year":"2017","unstructured":"Langley RG, Tsai T-F, Flavin S, Song M, Randazzo B, Wasfi Y, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase 3 NAVIGATE trial. Br J Dermatol. 2017;38(1):42\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"265_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"265_CR21","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s40265-014-0276-7","volume":"74","author":"A Markham","year":"2017","unstructured":"Markham A. Guselkumab: first global approval. Drugs. 2017;74(13):1555\u20138.","journal-title":"Drugs"},{"key":"265_CR22","unstructured":"Ault A. Guselkumab (Tremfya) Gets CHMP Backing for Plaque Psoriasis. 2017. https:\/\/www.medscape.com\/viewarticle\/885745 . Accessed Jan 24 2018."},{"key":"265_CR23","first-page":"1","volume":"6","author":"A Tonini","year":"2017","unstructured":"Tonini A, Gualtieri B, Panduri S, Romanelli M, Chiricozzi A. A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents. Expert Opin Biol Ther. 2017;6:1\u201314.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"265_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1517\/14728222.2014.889686","volume":"18","author":"A Chiricozzi","year":"2014","unstructured":"Chiricozzi A, Saraceno R, Chimenti MS, Guttman-Yassky E, Krueger JG. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? Expert Opin Ther Targets. 2014;18(5):513\u201325.","journal-title":"Expert Opin Ther Targets"},{"issue":"10","key":"265_CR25","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","volume":"31","author":"G Girolomoni","year":"2017","unstructured":"Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke WH, et al. The role of IL-23 and the IL-23\/T H 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616\u201326.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"265_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/ijms19010179","volume":"19","author":"A Chiricozzi","year":"2018","unstructured":"Chiricozzi A, Romanelli P, Volpe E, Borsellino G, Romanelli M. Scanning the Immunopathogenesis of Psoriasis. Int J Mol Sci. 2018;19(1):179.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"265_CR27","doi-asserted-by":"publisher","first-page":"13466","DOI":"10.1038\/ncomms13466","volume":"28","author":"P Kulig","year":"2016","unstructured":"Kulig P, Musiol S, Freiberger SN, Schreiner B, Gy\u00fclveszi G, Russo G, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016;28(7):13466.","journal-title":"Nat Commun"},{"issue":"9","key":"265_CR28","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","volume":"182","author":"L Fits van der","year":"2009","unstructured":"van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. J Immunol. 2009;182(9):5836\u201345.","journal-title":"J Immunol"},{"issue":"30","key":"265_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1196\/annals.1398.006","volume":"1109","author":"HD Chang","year":"2007","unstructured":"Chang HD, Radbruch A. The pro- and anti-inflammatory potential of interleukin-12. Ann N Y Acad Sci. 2007;1109(30):40\u20136.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"265_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.det.2014.09.002","volume":"33","author":"J Kim","year":"2015","unstructured":"Kim J, Krueger JG. The Immunopathogenesis of Psoriasis. Dermatol Clin. 2015;33(1):13\u201323.","journal-title":"Dermatol Clin"},{"issue":"3","key":"265_CR31","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/ijms11030789","volume":"11","author":"T Hamza","year":"2010","unstructured":"Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci. 2010;11(3):789\u2013806.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"265_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.immunol.16.1.495","volume":"16","author":"MK Gately","year":"1998","unstructured":"Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12\/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16(1):495\u2013521.","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"265_CR33","doi-asserted-by":"publisher","first-page":"682","DOI":"10.2174\/1568009617666170427102729","volume":"17","author":"X Lu","year":"2017","unstructured":"Lu X. Impact of IL-12 in cancer. Curr Cancer Drug Targets. 2017;17(8):682\u201397.","journal-title":"Curr Cancer Drug Targets"},{"issue":"11","key":"265_CR34","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00228-016-2110-5","volume":"72","author":"Y Zhuang","year":"2016","unstructured":"Zhuang Y, Calderon C, Marciniak SJ, Bouman-Thio E, Szapary P, Yang TY, et al. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics\/safety in healthy subjects and patients with moderate-to-severe psoriasis. Eur J Clin Pharmacol. 2016;72(11):1303\u201310.","journal-title":"Eur J Clin Pharmacol"},{"key":"265_CR35","first-page":"1","volume":"13","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Agarwal SK, Ilivanova E, Xu XL, Miao Y, Zhuang Y, et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann Rheum Dis. 2017;13:1\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"265_CR36","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","volume":"133","author":"H Sofen","year":"2014","unstructured":"Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032\u201340.","journal-title":"J Allergy Clin Immunol."},{"issue":"6","key":"265_CR37","first-page":"874","volume":"140","author":"KB Gordon","year":"2017","unstructured":"Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2017;140(6):874\u201388.","journal-title":"Br J Dermatol"},{"issue":"6","key":"265_CR38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ad.2015.02.005","volume":"106","author":"I Raposo","year":"2015","unstructured":"Raposo I, Torres T. Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermosifiliogr. 2015;106(6):452\u20137.","journal-title":"Actas Dermosifiliogr"},{"key":"265_CR39","doi-asserted-by":"crossref","unstructured":"Deodhar AA, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Barchuk W, Xu X, Hsia EC. Efficacy and safety results of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). http:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-results-of-guselkumab-an-anti-il23-monoclonal-antibody-in-patients-with-active-psoriatic-arthritis-over-24-weeks-a-phase-2a-randomized-double-blind-placebo-controlled-study\/ . Accessed Jan 24 2018.","DOI":"10.1136\/annrheumdis-2017-eular.1164"},{"issue":"3","key":"265_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.gtc.2017.05.013","volume":"46","author":"P Deepak","year":"2017","unstructured":"Deepak P, Sandborn WJ. Ustekinumab and anti-interleukin-23 agents in Crohn\u2019s disease. Gastroenterol Clin N Am. 2017;46(3):603\u201326.","journal-title":"Gastroenterol Clin N Am"},{"issue":"4","key":"265_CR41","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/bjd.13932","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Tha\u00e7i D, Reich K, Riedl E, Langley RG, Krueger JG, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930\u20139.","journal-title":"Br J Dermatol"},{"issue":"17","key":"265_CR42","first-page":"1","volume":"6736","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Tha\u00e7i D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet (London, England). 2017;6736(17):1\u201313.","journal-title":"Lancet (London, England)"},{"issue":"16","key":"265_CR43","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour J-P, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551\u201360.","journal-title":"N Engl J Med"},{"key":"265_CR44","unstructured":"Abbvie. Risankizumab meets all co-primary and ranked secondary endpoints, achieving significantly greater efficacy versus standard biologic therapies in three pivotal phase 3 psoriasis studies. 2017. https:\/\/news.abbvie.com\/news\/risankizumab-meets-all-co-primary-and-ranked-secondary-endpoints-achieving-significantly-greater-efficacy-versus-standard-biologic-therapies-in-three-pivotal-phase-3-psoriasis-studies.htm . Accessed Jan 24 2018."},{"issue":"10080","key":"265_CR45","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","volume":"389","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Sandborn WJ, D\u2019Haens G, Pan\u00e9s J, Kaser A, Ferrante M, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699\u2013709.","journal-title":"Lancet"},{"issue":"7","key":"265_CR46","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/14740338.2017.1338273","volume":"16","author":"B Verstockt","year":"2017","unstructured":"Verstockt B, Deleenheer B, Van Assche G, Vermeire S, Ferrante M. A safety assessment of biological therapies targeting the IL-23\/IL-17 axis in inflammatory bowel diseases. Expert Opin Drug Saf. 2017;16(7):809\u201321.","journal-title":"Expert Opin Drug Saf."},{"issue":"4","key":"265_CR47","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","volume":"43","author":"JR Maxwell","year":"2015","unstructured":"Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, et al. Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation. Immunity. 2015;43(4):739\u201350.","journal-title":"Immunity"},{"issue":"1","key":"265_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bjd.15015","volume":"177","author":"DM Saunte","year":"2017","unstructured":"Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47\u201362.","journal-title":"Br J Dermatol"},{"issue":"12","key":"265_CR49","first-page":"CD011535","volume":"12","author":"E Sbidian","year":"2017","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane database Syst Rev. 2017;12(12):CD011535.","journal-title":"Cochrane database Syst Rev"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-018-0265-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0265-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0265-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T11:13:21Z","timestamp":1570792401000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-018-0265-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["265"],"URL":"https:\/\/doi.org\/10.1007\/s40259-018-0265-6","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"assertion":[{"value":"22 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"\u00c1lvaro Machado has no conflicts of interest. Tiago Torres has participated in clinical trials sponsored by AbbVie, Amgen, and Novartis and has received honoraria for acting as a consultant and\/or as a speaker at events sponsored by AbbVie, Boehringer Ingelheim, Celgene, Janssen, Leo-Pharma, Lilly-Eli, MSD, Novartis, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}